Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 7.18% · OPTIONAL
· Ophthalmic Goods
RESEARCH SNAPSHOTRxSight, Inc.'s latest supported as-filed period reports revenue of $27.2M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 7.18% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -35.01% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -19.01% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 136.25% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -50.55% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 33.91% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 48.1%; Inventory / revenue moved 6175 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 66.9%; Operating cash flow decreased 118.0%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 27.3%; Capex / revenue moved 261 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 1.7%; SBC / revenue moved 199 bp higher.
2 evidence-backed componentsCurrent liabilities changed +294.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
RXST · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-386841SEC ↗4Sep 9, 2026Period Sep 5, 20260001193125-26-386840SEC ↗4Sep 9, 2026Period Sep 5, 20260001193125-26-386838SEC ↗4Sep 9, 2026Period Sep 5, 20260001193125-26-386837SEC ↗4Sep 2, 2026Period Aug 31, 20260001193125-26-380714SEC ↗4Sep 2, 2026Period Aug 31, 20260001193125-26-380713SEC ↗4Sep 2, 2026Period Aug 31, 20260001193125-26-380711SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Disposition To IssuerDirect | 98,367 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Disposition To IssuerDirect | 120,000 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Disposition To IssuerDirect | 92,200 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Disposition To IssuerDirect | 50,000 | — | — | Form 4 ↗ |
| Sep 5, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 27.40% · OPTIONAL
Inventory changed +48.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed -70.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -1525 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed -94.4% from the comparable as-filed period.
Operating cash flow changed -118.0% from the comparable as-filed period.
Operating margin changed -892 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-380710| Goldshleger IlyaChief Operating Officer |
| Disposition To IssuerDirect |
| 125,000 |
| — |
| — |
| Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Grant Or AwardDirect | 73,960 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Grant Or AwardDirect | 104,347 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Grant Or AwardDirect | 59,483 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Grant Or AwardDirect | 32,258 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Goldshleger IlyaChief Operating Officer | Grant Or AwardDirect | 93,984 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Disposition To IssuerDirect | 338,819 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Disposition To IssuerDirect | 200,000 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Disposition To IssuerDirect | 149,000 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Disposition To IssuerDirect | 215,000 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Grant Or AwardDirect | 254,751 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Grant Or AwardDirect | 173,913 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Grant Or AwardDirect | 96,129 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Kurtz Ronald M MDChief Medical Officer | Grant Or AwardDirect | 161,654 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Wilterding MarkChief Financial Officer | Disposition To IssuerDirect | 258,770 | — | — | Form 4 ↗ |
| Sep 5, 2026Filed Sep 9, 2026 | Wilterding MarkChief Financial Officer | Grant Or AwardDirect | 258,770 | — | — | Form 4 ↗ |